With further adjustment for self-reported smoking dose (Model 2), CPD, CYP2A6 activity remained associated with lung cancer risk (HR per unit increase in log-CYP2A6 activity = 1.52; 95% CI: 1.14–2.04), whereas, the lung cancer association with TNE was only of borderline statistical significance (HR per log-TNE increase = 1.53; 95% CI: 0.99–2.37) (Table 3, Model 2). The gene discussed is CYP2A6; the disease is lung carcinoma.